4.6 Article

Identifying novel genetic variants for brain amyloid deposition: a genome-wide association study in the Korean population

Journal

ALZHEIMERS RESEARCH & THERAPY
Volume 13, Issue 1, Pages -

Publisher

BMC
DOI: 10.1186/s13195-021-00854-z

Keywords

Alzheimer's disease; Amyloid-beta; Genome-wide association studies; Positron emission tomography

Funding

  1. National Research Foundation of Korea grant - Korean government (MSIP) [2018R1A1A3A04079255, 2014M3C7A1064752]
  2. ICT Creative Consilience program [IITP-2020-0-01821]
  3. Korea Health Technology RAMP
  4. D Project through the Korea Health Industry Development Institute - Ministry of Health and Welfare, Republic of Korea [HU21C0111, HI19C1132]
  5. Ministry of Science and ICT, Republic of Korea [2019RIA5A2026045]
  6. Korea Centers for Disease Control and Prevention [2018-ER6202-01, 4845-303]
  7. Korea Health Promotion Institute [2018-ER6202-01] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)
  8. National Research Foundation of Korea [2014M3C7A1064752, 2018R1A1A3A04079255] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)

Ask authors/readers for more resources

This study identified novel genetic variants associated with a decreased risk of A beta positivity in the Korean population, providing a potential therapeutic target for AD and emphasizing the importance of genetic studies in diverse populations.
Background: Genome-wide association studies (GWAS) have identified a number of genetic variants for Alzheimer's disease (AD). However, most GWAS were conducted in individuals of European ancestry, and non-European populations are still underrepresented in genetic discovery efforts. Here, we performed GWAS to identify single nucleotide polymorphisms (SNPs) associated with amyloid beta (A beta) positivity using a large sample of Korean population. Methods: One thousand four hundred seventy-four participants of Korean ancestry were recruited from multicenters in South Korea. Discovery dataset consisted of 1190 participants (383 with cognitively unimpaired [CU], 330 with amnestic mild cognitive impairment [aMCI], and 477 with AD dementia [ADD]) and replication dataset consisted of 284 participants (46 with CU, 167 with aMCI, and 71 with ADD). GWAS was conducted to identify SNPs associated with A beta positivity (measured by amyloid positron emission tomography). A beta prediction models were developed using the identified SNPs. Furthermore, bioinformatics analysis was conducted for the identified SNPs. Results: In addition to APOE, we identified nine SNPs on chromosome 7, which were associated with a decreased risk of A beta positivity at a genome-wide suggestive level. Of these nine SNPs, four novel SNPs (rs73375428, rs2903923, rs3828947, and rs11983537) were associated with a decreased risk of A beta positivity (p < 0.05) in the replication dataset. In a meta-analysis, two SNPs (rs7337542 and rs2903923) reached a genome-wide significant level (p < 5.0 x 10(-8)). Prediction performance for A beta positivity increased when rs73375428 were incorporated (area under curve = 0.75; 95% CI = 0.74-0.76) in addition to clinical factors and APOE genotype. Cis-eQTL analysis demonstrated that the rs73375428 was associated with decreased expression levels of FGL2 in the brain. Conclusion: The novel genetic variants associated with FGL2 decreased risk of A beta positivity in the Korean population. This finding may provide a candidate therapeutic target for AD, highlighting the importance of genetic studies in diverse populations.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available